---
title: "Patient-Derived Organoids: A New Frontier in ADC Development"
description: See how PDOs are accelerating ADC development and explore real-world case studies where our insights guided key preclinical development decisions
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

![ddw-2025-logo](https://resources.huborganoids.nl/hs-fs/hubfs/ddw-2025-logo.png?width=300&height=65&name=ddw-2025-logo.png)

# Patient-Derived Organoids: A New Frontier in ADC Development

### See how PDOs are accelerating ADC development and explore real-world case studies where our insights guided key preclinical development decisions

**See why biotech innovators are choosing organoid technology**

download factsheet

## Why choose Organoid Technology for your ADC program?

![section-img2](https://www.huborganoids.nl/wp-content/uploads/2024/09/icon-adc-organoid-screen.png)

Traditional ADC models like 2D cell lines and PDXs often fail to predict clinical outcomes, leading to high attrition and dose-limiting toxicities. Patient-derived organoids (PDOs) provide a more predictive alternative. These 3D tumor models preserve patient-specific architecture and genetics, enabling accurate assessment of ADC efficacy and off-target toxicities across both tumor and healthy tissues.

## What you'll learn:

- How patient-derived organoids (PDOs) outperform traditional cell lines and PDX models in ADC development
- Data showcasing how HUB Organoids capture the diversity of patient responses
- An overview of our comprehensive ADC services portfolio
- Two in-depth case studies illustrating how we’ve helped clients make confident, data-driven preclinical decisions

download factsheet

## Discover our ADC development solutions

Whether you need to assess antigen expression in patient-derived models, evaluate ADC potency and off-target toxicities, or run basket screens across multiple cancer indications, our tailored service packages are designed to accelerate your program.

[book a consultation](https://www.huborganoids.nl/antibody-drug-conjugate-organoid-solutions/)

![section-img3](https://resources.huborganoids.nl/hs-fs/hubfs/lab-rounded-corners.png?width=600&height=478&name=lab-rounded-corners.png)

×

### Download Factsheet

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*